Perspectives
Adherence can decrease hospitalizations for inflammatory bowel diseases
High-cost biologic therapies are associated with two-fold decrease in hospitalizations
August 21, 2019Adherence to high-cost biologic therapies are associated with two-fold decrease in hospitalizations for key inflammatory bowel diseases
This study showed that members with Crohn’s disease or ulcerative colitis who were adherent to biologic therapy had approximately two-fold lower odds of hospitalization. Hospitalizations are costly from a direct and indirect cost perspective. To prevent one hospitalization through improved adherence, plans would incur substantial additional biologic therapy cost. It’s important to consider these findings in clinical care programs and as justification in value-based contracting.
Related news
Perspectives
April 25, 2024
Clinical News: April 2024
Your monthly source for drug information highlights
Perspectives
April 25, 2024
Drug Approvals Monthly Update: April 2024
This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…
Perspectives
April 25, 2024
Drug Approvals Quarterly Update: April 2024
This wrap-up provides a review of newly approved drugs, recent drug launches, new…